Pfizer’s Lorbrena extends life for patients with ALK-Positive Advanced Lung Cancer

Pfizer's Lorbrena (lorlatinib) has shown significant benefits for patients with a rare type of lung cancer, specifically ALK-positive non-small cell lung cancer (NSCLC). Recent results from the phase 3 CROWN trial demonstrate that Lorbrena markedly improves progression-free survival (PFS) and overall response rates compared to crizotinib (Xalkori), the previous standard treatment. Pfizer’s lung cancer drug Lorbrena can extend life for patients with a rare form of the disease for years longer than other drugs, according to new researchers.

“If you are diagnosed with stage 4 lung cancer, it’s important to ask your oncologist to send off next-generation sequencing,” she said. “If you have an ALK fusion, you should absolutely be on targeted therapy."